HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials

por Volk, JE, Hessol, NA, Gray, GE, Kublin, JG, Churchyard, G, Mlisana, K, Nchabeleng, M, Buchbinder, SP, Bekker, L
Publicado 2012